We have recently cared for an infant with neonatal hypoglycemia secondary to endogenous organic, hyperinsulinism (blood glucose 22mg/dl; insulin 92uU/ml) that was refractory to diazoxide ...

Research and development expenses were $12.6 million for the second quarter of fiscal 2025, compared with $12.0 million for the same period a year ago, with the increase primarily attributable to ...

Rezolute, Inc. announced that the Data Monitoring Committee (DMC) has reviewed the open-label arm of its Phase 3 sunRIZE study for the treatment of congenital hyperinsulinism with ersodetug in ...

Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug ...

Congenital hyperinsulinism (HI) is the most common cause of recurrent and persistent hypoglycemia in children. Patients with congenital HI typically present with signs or symptoms of hypoglycemia ...

REDWOOD CITY, Calif. - Rezolute , Inc. (NASDAQ:RZLT), a biopharmaceutical company with a market capitalization of $303.62 million and impressive recent momentum (up 13.91% in the past week), announced ...

provided an update on its Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due to congenital hyperinsulinism or HI. The open-label arm of the study, which enrolled 8 infant ...

JMP Securities adjusted its financial outlook for Rezolute (NASDAQ:RZLT), increasing the price target to $9.00 from the previous $8.00, while keeping a Market Outperform rating on the stock. Currently ...